Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

O’Melveny recruits IP litigator for New York office
article
O’Melveny has hired life sciences patent litigator Gregory Morris for its New York office as a partner in its IP and technology practice group.   30 August 2022
Novartis sued over blockbuster heart failure drug
Generics
Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.   30 August 2022
Jones Day hires new counsel for New York IP practice
article
Jones Day has announced that Yi Han Dulkeith has joined the firm’s IP practice in New York.   18 August 2022
Pharma
A Virginia court was unconvinced that the Hatch-Waxman Act did not apply.   14 July 2022
Pharma
The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.   5 July 2022
Pharma
Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.   28 June 2022
Pharma
Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.   16 June 2022
article
The World Trade Organization has issued draft texts relating to its IP response to the COVID-19.   14 June 2022
Americas
Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt.   9 June 2022
Generics
Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.   9 June 2022

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.